Obesity and heart disease

Years funded:
2015 - 2018

Obese patients with type 2 diabetes pose one of the largest burdens on public health in Australia.

People who are obese largely die of cardiovascular disease. Adding to this is the fact that reversal of heart disease (atherosclerotic lesion regression) is limited in people with obesity and type 2 diabetes, even when blood cholesterol levels come under control. This suggests that factors other than lipids affect disease reversal in these patients - a problem that it is vital to address. Hence, the need to identify what causes the increased incidence of cardiovascular disease in obese, diabetic patients.

This project will explore how and why obesity impairs atherosclerotic lesion regression. Dr Murphy aims to identify pathways that can be targeted to aid disease reversal in obese patients, while achieving weight loss to significantly reduce cardiovascular disease risk

Researcher Profile

Assistant Professor Andrew Murphy

Institute: Baker Heart and Diabetes Institute
Learn More